Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05153200
Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 46
- Registration Number
- NCT05090124
- Locations
- 🇬🇧
Addenbrooks Hopsital, Cambridge, United Kingdom
🇬🇧Neil Basu, Glasgow, United Kingdom
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 425
- Registration Number
- NCT05073315
- Locations
- 🇺🇸
Johnson Dermatology Clinic, Fort Smith, Arkansas, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05015335
- Locations
- 🇨🇳
Peking University Medical College Hospital, Beijing, China
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 151
- Registration Number
- NCT04988308
- Locations
- 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸Forcare Clinical Research, Inc., Tampa, Florida, United States
🇺🇸Allcutis Research, Beverly, Massachusetts, United States
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 338
- Registration Number
- NCT04909801
- Locations
- 🇮🇹
Local Institution - 0083, Catania, Italy
🇮🇹Local Institution - 0077, Pavia, Italy
🇺🇸Local Institution - 0036, Fullerton, California, United States
Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04882683
- Locations
- 🇨🇳
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong, Shandong, China
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 178
- Registration Number
- NCT04870203
- Locations
- 🇫🇷
CH de Belfort - service de rhumatologie, Belfort, France
🇫🇷CHU de Brest - Service de rhumatologie, Brest, France
🇫🇷Polyclinique de Limoges - service de rhumatologie, Limoges, France
Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Hospital San Carlos, Madrid
- Target Recruit Count
- 192
- Registration Number
- NCT04798755
- Locations
- 🇪🇸
Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
CHronic Nonbacterial Osteomyelitis International Registry
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.